JP2023549605A5 - - Google Patents

Info

Publication number
JP2023549605A5
JP2023549605A5 JP2023528411A JP2023528411A JP2023549605A5 JP 2023549605 A5 JP2023549605 A5 JP 2023549605A5 JP 2023528411 A JP2023528411 A JP 2023528411A JP 2023528411 A JP2023528411 A JP 2023528411A JP 2023549605 A5 JP2023549605 A5 JP 2023549605A5
Authority
JP
Japan
Prior art keywords
bedaquiline
weeks
combination product
administered
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549605A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/081193 external-priority patent/WO2022101244A1/en
Publication of JP2023549605A publication Critical patent/JP2023549605A/ja
Publication of JP2023549605A5 publication Critical patent/JP2023549605A5/ja
Pending legal-status Critical Current

Links

JP2023528411A 2020-11-12 2021-11-10 非結核性マイコバクテリア疾患の治療におけるベダキリン、エタンブトール、及びマクロライドの組合せ Pending JP2023549605A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063113149P 2020-11-12 2020-11-12
US63/113,149 2020-11-12
PCT/EP2021/081193 WO2022101244A1 (en) 2020-11-12 2021-11-10 Combination of bedaquiline, ethambutol and a macrolide in the treatment of nontuberculous mycobacterial diseases

Publications (2)

Publication Number Publication Date
JP2023549605A JP2023549605A (ja) 2023-11-28
JP2023549605A5 true JP2023549605A5 (https=) 2024-11-27

Family

ID=78695693

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528411A Pending JP2023549605A (ja) 2020-11-12 2021-11-10 非結核性マイコバクテリア疾患の治療におけるベダキリン、エタンブトール、及びマクロライドの組合せ

Country Status (7)

Country Link
US (1) US20230346770A1 (https=)
EP (1) EP4243800A1 (https=)
JP (1) JP2023549605A (https=)
KR (1) KR20230107275A (https=)
CN (1) CN116406270A (https=)
TW (1) TW202233168A (https=)
WO (1) WO2022101244A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250169098A (ko) 2024-05-24 2025-12-02 주식회사 에이엔제이사이언스 티오펩타이드 화합물을 포함하는 비결핵 항산균 감염증의 예방, 개선 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1527050T3 (da) 2002-07-25 2010-07-19 Janssen Pharmaceutica Nv Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer
AU2005249231B2 (en) 2004-05-28 2010-11-11 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
UA97813C2 (uk) 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
LT3250182T (lt) * 2015-01-27 2023-07-10 Janssen Pharmaceutica Nv Dispersinės kompozicijos
JOP20200004B1 (ar) * 2017-07-14 2023-09-17 Janssen Pharmaceutica Nv تركيبات طويلة المفعول
WO2020144197A1 (en) * 2019-01-09 2020-07-16 Janssen Pharmaceutica Nv Combination in the treatment of nontuberculous mycobacterial diseases

Similar Documents

Publication Publication Date Title
RU2314810C2 (ru) Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0 (2,11).0(4,9)] гексадека-2( 11),3,5,7,9-пентаена
ES2925246T3 (es) Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina
JP5726766B2 (ja) ニタゾキサニドの制御放出医薬配合物
ES2524408T5 (es) Composiciones terapéuticas que comprenden rilpivirina HCl y tenofovir disoproxil fumarato
RU2404750C2 (ru) Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту
HUE029677T2 (hu) Készítmények centrálisan mediált émelygés és hányás kezelésére
JPH06102622B2 (ja) 肥満の治療
JP2006514092A5 (https=)
JP2019517542A5 (https=)
JP2010538066A5 (https=)
KR101951220B1 (ko) 조합 als 치료법
JP2021509395A5 (https=)
CZ2004232A3 (cs) Jednorázová dávka azithromycinu
JP2022549621A5 (https=)
JP2023549605A5 (https=)
JP2024539476A5 (https=)
ES2286716T3 (es) Composicion farmaceutica de liberacion controlada y proceso para preparar la misma.
JP2022177119A5 (https=)
US20160184231A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
JP2021503448A5 (https=)
US20090306204A1 (en) Pharmaceutical Composition Comprising Cyclobenzaprine and Aceclofenac in Association
JP2006508118A5 (https=)
CN102327599A (zh) 用于治疗骨髓增生异常综合征的组合物和方法
JP2023533472A5 (https=)
JP2024531799A5 (https=)